Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 627-632

  An, She Juan ^a   Huang, Yi Sheng ^a   Chen, Zhi Hong ^a   Su, Jian ^a   Yang, Yan ^a   Chen, Jian Guang ^a   Yan, Hong Hong ^a   Lin, Qiu Xiong ^a   Yang, Jin Ji ^a   Yang, Xue Ning ^a   Zhou, Qing ^a   Zhang, Xu Chao ^a   Wu, Yi Long ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Bevacizumab; Laminin 5; Survival; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; HEMOGLOBIN; KALININ; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CELL ADHESION MOLECULE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE SEQUENCE; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; TREATMENT DURATION; ADENOCARCINOMA; CANCER STAGING; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; LARGE CELL CARCINOMA; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION MOLECULES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, GENETIC; PROGNOSIS; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84866287860     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9924-x     Document Type: Article

References (24)

1. Wheatley-Price P, Shepherd FA. Targeting angiogenesis in the treatment of lung cancer. J Thorac Oncol. 2008;3:1173-84.
2. Sandler A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med. 2006;355: 2542-50.
3. Reck M, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010;21:1804-9.
4. Amir E, et al. Antivascular agents for non-small cell lung cancer: current status and future directions. Expert Opin Investig Drugs. 2009;18:1667-86.
5. Crinò L, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 2010;11: 733-40.
6. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-76.
7. Willett CG, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10:145-7.
8. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev. 2005;15: 102-11.
9. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58-62.
10. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7:987-9.
11. Saijo N, Kenmotsu H. Recent development of molecular-targeted drugs in lung cancer. Intern Med. 2010;49:1923-34.
12. Inai T, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004;165:35-52.
13. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487-91.
14. Schneider BP, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008;26:4672-8.
15. An SJ, et al. The -271 G[A polymorphism of kinase insert domain-containing receptor gene regulates its transcription level in patients with non-small cell lung cancer. BMC Cancer. 2009; 9:144.
16. Huang YS, An SJ, Chen ZH, Wu YL. Three cases of severe hepatic impairment caused by erlotinib. Br J Clin Pharmacol. 2009;68:464-7.
17. Vroling L, et al. CD133 + circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients. Br J Cancer. 2010;102:268-75.
18. Wagstaff AJ, Keam SJ, McCormack PL. Bevacizumab plus platinum-based chemotherapy: in advanced non-small cell lung cancer. Bio Drugs. 2009;23:187-96.
19. Sandler A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med. 2006;355:2542-50.
20. Nikolinakos PG, et al. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res. 2010;70:2171-9.
21. Hanrahan EO, et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small cell lung cancer. J Clin Oncol. 2010;28:193-201.
22. Miyazaki K. Laminin-5 (laminin-332): unique biological activity and role in tumor growth and invasion. Cancer Sci. 2006;97: 91-8.
23. Fukai Y, et al. Correlation between laminin-5 gamma2 chain and epidermal growth factor receptor expression in esophageal squamous cell carcinomas. Oncology. 2005;69:71-80.
24. Giannelli G, et al. ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells. Biochem Pharmacol. 2006;71:479-85.